Coalition for Epidemic Preparedness Innovations (CEPI) | IAS Target IAS Target

Coalition for Epidemic Preparedness Innovations

The Coalition for Epidemic Preparedness Innovations (CEPI) is a "public-private coalition that aims to disrupt epidemics by speeding up the development of vaccines". The concept is to develop early phases of vaccines without knowing the details for the form in which the infection will appear, but will still cut down the time to tailor the eventual vaccine to be effective to the epidemic.
A global coalition to create new vaccines for emerging infectious diseases, designed to give the world an insurance policy against epidemics, was recently launched at the World Economic Forum in Davos, Switzerland.

CEPI focus:

On 11 diseases including ( Lassa fever, Marburg fever, Middle East Respiratory Syndrome (MERS), SARS, Nipah virus, Rift Valley fever, chikungunya, and others)

CEPI supported by:

  • The Wellcome Trust,
  • The World Economic Forum,
  • The Bill and Melinda Gates Foundation,
  • The governments of Norway, Germany, Japan and India.

The latest works of CEPI:

Invested $37.5 million in Austria-based Themis Bioscience and $56 million in US-based Inovio Pharmaceuticals, Inc. to develop vaccine candidates against Lassa fever and MERS.


CEPI published a study in the Lancet, which estimated the costs of developing vaccines for diseases that could soar into global humanitarian crises. CEPI focused on 11 diseases that cause relatively few deaths at present and primarily strike the poor. CEPI estimated that it would cost between $2.8 billion and $3.7 billion to develop at least one vaccine for each of them. CEPI also hopes to shorten the time it takes to create new vaccines to protect against viruses that emerge suddenly as public health threats, as Zika did recently.